Dr. Peter Riedell, MD
Claim this profileUniversity of Chicago
Expert in Lymphoma
Studies Diffuse Large B-Cell Lymphoma
16 reported clinical trials
27 drugs studied
Area of expertise
1Lymphoma
Global LeaderCD19 positive
BCL6 positive
Philadelphia chromosome positive
2Diffuse Large B-Cell Lymphoma
CD19 positive
MYC positive
BCL2 positive
Affiliated Hospitals
Clinical Trials Peter Riedell, MD is currently running
JCAR017
for Chronic Leukemia or Lymphoma
This trial tests JCAR017, a therapy using modified immune cells, in adults with hard-to-treat CLL or SLL. It aims to see if these enhanced immune cells can better fight the cancer.
Recruiting1 award Phase 1 & 2
Rituximab vs Mosunetuzumab
for Follicular Lymphoma
This phase III trial compares the effectiveness of rituximab to mosunetuzumab in treating patients with follicular lymphoma with a low tumor burden. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. It is not yet known if giving rituximab or mosunetuzumab works better in treating patients with follicular lymphoma with a low tumor burden.
Recruiting2 awards Phase 313 criteria
More about Peter Riedell, MD
Clinical Trial Related8 years of experience running clinical trials · Led 16 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Peter Riedell, MD has experience with
- Ibrutinib
- Rituximab
- CLBR001
- Duvelisib
- Autologous Hematopoietic Stem Cell Transplantation
- SWI019
Breakdown of trials Peter Riedell, MD has run
Lymphoma
Diffuse Large B-Cell Lymphoma
Chronic Lymphocytic Leukemia
Mantle Cell Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Peter Riedell, MD specialize in?
Peter Riedell, MD focuses on Lymphoma and Diffuse Large B-Cell Lymphoma. In particular, much of their work with Lymphoma has involved CD19 positive patients, or patients who are BCL6 positive.
Is Peter Riedell, MD currently recruiting for clinical trials?
Yes, Peter Riedell, MD is currently recruiting for 3 clinical trials in Chicago Illinois. If you're interested in participating, you should apply.
Are there any treatments that Peter Riedell, MD has studied deeply?
Yes, Peter Riedell, MD has studied treatments such as Ibrutinib, Rituximab, CLBR001.
What is the best way to schedule an appointment with Peter Riedell, MD?
Apply for one of the trials that Peter Riedell, MD is conducting.
What is the office address of Peter Riedell, MD?
The office of Peter Riedell, MD is located at: University of Chicago, Chicago, Illinois 60637 United States. This is the address for their practice at the University of Chicago.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.